Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
Daniel Edmonston(Duke University), Neha J. Pagidipati(Alnylam Pharmaceuticals (United States)), Hillary Mulder(Clinical Research Institute), Christina M. Shay, Kelly J. Hunt(Medical University of South Carolina), Wenke Hwang(Penn State Milton S. Hershey Medical Center), Keith Marsolo(Duke University), Raj C. Shah, Javed Butler(University of Mississippi Medical Center), Hayden B. Bosworth(Duke University), W Schuyler Jones(Duke University), Alex R. Chang, Vivian Fonseca(Tulane University), Faraz S. Ahmad(Northwestern University), Ajaykumar Rao(Temple University), Alanna M. Chamberlain, Adriana M. Hung(Vanderbilt University), Elizabeth Lydon(Duke University), Daniel E. Ford(Johns Hopkins University), Isabelle Ayoub(The Ohio State University Wexner Medical Center), Zachary Lampron(Duke University), Howard S. Gordon(University of Illinois Chicago), Karen Chiswell(Amyloidosis Foundation)
Cited by 31
Related Papers
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Heart Disease and Stroke Statistics—2021 Update
|Circulation|2021|5.7k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k